A test developed by a Madison company to better track cancer DNA in the blood stream will now be covered by Medicare.

The test claims to analyse epigenomic and genomic data from circulating, cell-free DNA obtained from a simple blood draw.

Methylation changes in microbiome-derived cfRNA enable more accurate CRC diagnosis than traditional DNA or abundance-based ...

Could a sea cucumber sugar transform cancer care? A new study reveals its enzyme-blocking potential and safer profile ...

Lack of early detection: One risk factor is also the fact that there are no early detection methods for pancreatic cancer, unlike breast or colon cancer. Future research will focus on blood tests ...

Trump administration policy tug-of-war between big medical groups that want COVID vaccines back on CDC schedule for healthy ...

Researchers from the University of British Columbia (UBC) have uncovered a direct connection between high insulin ...

There was a special delivery for cancer patients at St. Elizabeth Hospital on Monday afternoon thanks to a woman who has made ...

Pancreatic cancer (PC) remains one of the most lethal cancers worldwide, with only 13% of patients surviving more than five ...

Seven warning signs of pancreatic cancer you shouldn't ignore as these subtle symptoms often get dismissed but could save ...

Shares of Liminatus Pharma rose after the company shared plans to collaborate on developing a diagnostic kit for detecting pancreatic cancer. The stock advanced 3.7%, to $9.35, in after-hours trading ...